New Drugs in the Pipeline for Prostate Cancer

The following question is for the Ask Dr Barken
Call In Show on Tuesday, Jan. 17th at 6pm Pacific
Time.  Dial 1-877-727-3301 to hear the program.
Question of the week:  
What is the difference between hormone-insensitive,
hormone-refractory, hormone-independent and
castration-resistant prostate cancer?
 
Dr. Barken answers this question and introduces
a video  lecture about the subject.
Video Lecture:
Charles Drake, M.D. of Johns Hopkins discusses new
drugs in the pipeline for prostate cancer.  This presentation
took place at the annual Prostate Cancer Research Institute
public conference 2011.
Article:
MDV3100 for the treatment of prostate cancer. 
De-Bono JS.,  Expert Opin Investig Drugs. 2012 Jan 10
This entry was posted in Immune Therapy, Metastatic Disease, Metastatic Prostate Cancer Disease, Prostate Cancer, Testosterone, Treatments for Prostate Cancer. Bookmark the permalink.